Therapeutic Value of Drugs Lower for Supplemental Versus First Indications
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
FRIDAY, July 7, 2023 -- For drugs approved in the United States and Europe, the therapeutic value of supplemental indications is lower than for first indications, according to a study published online July 5 in The BMJ.
Kerstin N. Vokinger, M.D., J.D., Ph.D., from the University of Zurich, and colleagues analyzed the therapeutic value of supplemental indications compared with first indications for drugs approved in the United States and Europe in a retrospective cohort study. The study included 124 and 335 first and supplemental indications, respectively, approved by the U.S. Food and Drug Administration, and 88 and 215 first and supplemental indications, respectively, approved by the European Medicines Agency, between 2011 and 2020. The largest subset of indications was for cancer disorders. Therapeutic ratings were available for 86 percent of first and 53 percent of supplemental indications in the United States, and for 99 percent of first and 86 percent of supplemental indications in Europe.
The researchers found that among FDA approved indications, 41 versus 34 percent of first and supplemental indications had high therapeutic value ratings, compared with 47 versus 36 percent in Europe. Among FDA approvals, second and third indication approvals were less likely to have a high value rating (relative ratios, 0.64 and 0.55, respectively) compared with the first indication approval when the sample was restricted to the first three approved indications. Similar findings were seen for Europe.
"When first or supplemental indications do not offer added therapeutic value over other available treatments, that information should be clearly communicated to patients and physicians and reflected in the price of the drug," the authors write.
Several authors disclosed ties to the pharmaceutical industry; one author is an expert witness in a qui tam suit against Biogen.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted July 2023
Read this next
342 Cardiology Clinics Acquired by Private Equity Firms in 2013 to 2023
WEDNESDAY, July 3, 2024 -- From 2013 to 2023, 342 cardiology clinics were acquired by private equity firms, with 94.7 percent of the acquisitions occurring between 2021 and 2023...
AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours
WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...
Vaginal Cancer Incidence Increasing Globally
WEDNESDAY, July 3, 2024 -- The incidence of vaginal cancer is increasing globally, according to a study published online June 25 in BJOG: An International Journal of Obstetrics...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.